Correction to Novartis Wins FDA Approval for Expanded Prostate Cancer Treatment Article on July 31
Dow Jones2026/08/03 21:37Novartis's Pluvicto was approved by the Food and Drug Administration for use in combination with an androgen receptor pathway inhibitor. "Novartis Wins FDA Approval for Expanded Prostate Cancer Treatment For Pluvicto," at 5:06 p.m. ET on July 31, incorrectly said Pluvicto was approved for use in combination with an androgen receptor pathway inhibitor and androgen deprivation therapy.
(END) Dow Jones Newswires
August 03, 2026 17:37 ET (21:37 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
South32 submits business update presentation to National Storage Mechanism
Eurozone Bond Yields Rise but Stay Below Monday's Peaks -- Market Talk
Gold: Fed risk keeps bullion vulnerable – ING
Carlyle (CG.US) further expands energy business, acquires Parallax for 1 billion Canadian dollars
Carlyle's newly established company plans to acquire Parallax for approximately 1 billion Canadian dollars, continuing its expansion of light crude oil assets in Canada.
Crypto prices
More
